Similarity Score |
Similarity Level |
Drug ID |
Developmental Stage |
0.9267 |
High Similarity |
NPD4381 |
Clinical (unspecified phase) |
0.8861 |
High Similarity |
NPD7054 |
Approved |
0.8861 |
High Similarity |
NPD7804 |
Clinical (unspecified phase) |
0.8805 |
High Similarity |
NPD7074 |
Phase 3 |
0.8805 |
High Similarity |
NPD7472 |
Approved |
0.875 |
High Similarity |
NPD6797 |
Phase 2 |
0.8696 |
High Similarity |
NPD7251 |
Discontinued |
0.869 |
High Similarity |
NPD1552 |
Clinical (unspecified phase) |
0.869 |
High Similarity |
NPD1550 |
Clinical (unspecified phase) |
0.8679 |
High Similarity |
NPD3818 |
Discontinued |
0.8642 |
High Similarity |
NPD7808 |
Phase 3 |
0.863 |
High Similarity |
NPD1549 |
Phase 2 |
0.8618 |
High Similarity |
NPD4380 |
Phase 2 |
0.8528 |
High Similarity |
NPD4338 |
Clinical (unspecified phase) |
0.8526 |
High Similarity |
NPD7075 |
Discontinued |
0.8506 |
High Similarity |
NPD1934 |
Approved |
0.8467 |
Intermediate Similarity |
NPD6799 |
Approved |
0.8466 |
Intermediate Similarity |
NPD6559 |
Discontinued |
0.8452 |
Intermediate Similarity |
NPD2393 |
Clinical (unspecified phase) |
0.8387 |
Intermediate Similarity |
NPD6801 |
Discontinued |
0.8333 |
Intermediate Similarity |
NPD7096 |
Clinical (unspecified phase) |
0.8323 |
Intermediate Similarity |
NPD6167 |
Clinical (unspecified phase) |
0.8323 |
Intermediate Similarity |
NPD6166 |
Phase 2 |
0.8323 |
Intermediate Similarity |
NPD6168 |
Clinical (unspecified phase) |
0.8289 |
Intermediate Similarity |
NPD4378 |
Clinical (unspecified phase) |
0.8276 |
Intermediate Similarity |
NPD1240 |
Approved |
0.8224 |
Intermediate Similarity |
NPD1511 |
Approved |
0.8217 |
Intermediate Similarity |
NPD2801 |
Approved |
0.8205 |
Intermediate Similarity |
NPD7411 |
Suspended |
0.8182 |
Intermediate Similarity |
NPD5403 |
Approved |
0.8176 |
Intermediate Similarity |
NPD1510 |
Phase 2 |
0.8165 |
Intermediate Similarity |
NPD3817 |
Phase 2 |
0.8165 |
Intermediate Similarity |
NPD8443 |
Clinical (unspecified phase) |
0.8163 |
Intermediate Similarity |
NPD1607 |
Approved |
0.8146 |
Intermediate Similarity |
NPD1878 |
Clinical (unspecified phase) |
0.8141 |
Intermediate Similarity |
NPD6599 |
Discontinued |
0.8133 |
Intermediate Similarity |
NPD970 |
Clinical (unspecified phase) |
0.8121 |
Intermediate Similarity |
NPD2796 |
Approved |
0.8117 |
Intermediate Similarity |
NPD1512 |
Approved |
0.8113 |
Intermediate Similarity |
NPD3882 |
Suspended |
0.8113 |
Intermediate Similarity |
NPD4868 |
Clinical (unspecified phase) |
0.8052 |
Intermediate Similarity |
NPD5401 |
Approved |
0.8052 |
Intermediate Similarity |
NPD7410 |
Clinical (unspecified phase) |
0.8014 |
Intermediate Similarity |
NPD1091 |
Approved |
0.7987 |
Intermediate Similarity |
NPD7819 |
Suspended |
0.7937 |
Intermediate Similarity |
NPD5402 |
Approved |
0.7914 |
Intermediate Similarity |
NPD6959 |
Discontinued |
0.7898 |
Intermediate Similarity |
NPD1653 |
Approved |
0.7891 |
Intermediate Similarity |
NPD6859 |
Clinical (unspecified phase) |
0.7881 |
Intermediate Similarity |
NPD1551 |
Phase 2 |
0.7843 |
Intermediate Similarity |
NPD2800 |
Approved |
0.78 |
Intermediate Similarity |
NPD6651 |
Approved |
0.7792 |
Intermediate Similarity |
NPD4628 |
Phase 3 |
0.7771 |
Intermediate Similarity |
NPD7852 |
Clinical (unspecified phase) |
0.7751 |
Intermediate Similarity |
NPD7993 |
Clinical (unspecified phase) |
0.7714 |
Intermediate Similarity |
NPD7879 |
Clinical (unspecified phase) |
0.7707 |
Intermediate Similarity |
NPD2533 |
Approved |
0.7707 |
Intermediate Similarity |
NPD2534 |
Approved |
0.7707 |
Intermediate Similarity |
NPD2532 |
Approved |
0.765 |
Intermediate Similarity |
NPD7584 |
Approved |
0.7636 |
Intermediate Similarity |
NPD5494 |
Approved |
0.7616 |
Intermediate Similarity |
NPD230 |
Phase 1 |
0.7616 |
Intermediate Similarity |
NPD8312 |
Approved |
0.7616 |
Intermediate Similarity |
NPD8313 |
Approved |
0.7613 |
Intermediate Similarity |
NPD1243 |
Approved |
0.7613 |
Intermediate Similarity |
NPD7421 |
Clinical (unspecified phase) |
0.7613 |
Intermediate Similarity |
NPD1652 |
Phase 2 |
0.761 |
Intermediate Similarity |
NPD920 |
Approved |
0.7586 |
Intermediate Similarity |
NPD9717 |
Approved |
0.7574 |
Intermediate Similarity |
NPD3751 |
Discontinued |
0.7564 |
Intermediate Similarity |
NPD3750 |
Approved |
0.7561 |
Intermediate Similarity |
NPD7768 |
Phase 2 |
0.7551 |
Intermediate Similarity |
NPD1203 |
Approved |
0.7546 |
Intermediate Similarity |
NPD1465 |
Phase 2 |
0.7546 |
Intermediate Similarity |
NPD8455 |
Phase 2 |
0.7545 |
Intermediate Similarity |
NPD3787 |
Discontinued |
0.7545 |
Intermediate Similarity |
NPD6232 |
Discontinued |
0.7529 |
Intermediate Similarity |
NPD5844 |
Phase 1 |
0.7517 |
Intermediate Similarity |
NPD422 |
Phase 1 |
0.7517 |
Intermediate Similarity |
NPD6832 |
Phase 2 |
0.7515 |
Intermediate Similarity |
NPD3749 |
Approved |
0.7515 |
Intermediate Similarity |
NPD7473 |
Discontinued |
0.75 |
Intermediate Similarity |
NPD1933 |
Approved |
0.75 |
Intermediate Similarity |
NPD6980 |
Clinical (unspecified phase) |
0.7485 |
Intermediate Similarity |
NPD7199 |
Phase 2 |
0.7484 |
Intermediate Similarity |
NPD642 |
Clinical (unspecified phase) |
0.7468 |
Intermediate Similarity |
NPD643 |
Clinical (unspecified phase) |
0.7442 |
Intermediate Similarity |
NPD5953 |
Discontinued |
0.7434 |
Intermediate Similarity |
NPD1613 |
Approved |
0.7434 |
Intermediate Similarity |
NPD1612 |
Clinical (unspecified phase) |
0.7427 |
Intermediate Similarity |
NPD7286 |
Phase 2 |
0.7419 |
Intermediate Similarity |
NPD2935 |
Discontinued |
0.7418 |
Intermediate Similarity |
NPD6782 |
Approved |
0.7418 |
Intermediate Similarity |
NPD6779 |
Approved |
0.7418 |
Intermediate Similarity |
NPD6778 |
Approved |
0.7418 |
Intermediate Similarity |
NPD6776 |
Approved |
0.7418 |
Intermediate Similarity |
NPD6777 |
Approved |
0.7418 |
Intermediate Similarity |
NPD6780 |
Approved |
0.7418 |
Intermediate Similarity |
NPD6781 |
Approved |
0.7397 |
Intermediate Similarity |
NPD1547 |
Clinical (unspecified phase) |
0.7389 |
Intermediate Similarity |
NPD2654 |
Approved |
0.7386 |
Intermediate Similarity |
NPD447 |
Suspended |
0.738 |
Intermediate Similarity |
NPD8151 |
Discontinued |
0.7378 |
Intermediate Similarity |
NPD37 |
Approved |
0.7368 |
Intermediate Similarity |
NPD7228 |
Approved |
0.7365 |
Intermediate Similarity |
NPD919 |
Approved |
0.7365 |
Intermediate Similarity |
NPD6234 |
Discontinued |
0.7361 |
Intermediate Similarity |
NPD9545 |
Approved |
0.7355 |
Intermediate Similarity |
NPD7033 |
Discontinued |
0.7349 |
Intermediate Similarity |
NPD4967 |
Phase 2 |
0.7349 |
Intermediate Similarity |
NPD4966 |
Approved |
0.7349 |
Intermediate Similarity |
NPD4965 |
Approved |
0.7348 |
Intermediate Similarity |
NPD8090 |
Clinical (unspecified phase) |
0.732 |
Intermediate Similarity |
NPD943 |
Approved |
0.7308 |
Intermediate Similarity |
NPD6100 |
Approved |
0.7308 |
Intermediate Similarity |
NPD6099 |
Approved |
0.7299 |
Intermediate Similarity |
NPD7685 |
Pre-registration |
0.7297 |
Intermediate Similarity |
NPD7435 |
Discontinued |
0.7294 |
Intermediate Similarity |
NPD7184 |
Clinical (unspecified phase) |
0.7278 |
Intermediate Similarity |
NPD1247 |
Approved |
0.7273 |
Intermediate Similarity |
NPD5124 |
Phase 1 |
0.7273 |
Intermediate Similarity |
NPD5123 |
Clinical (unspecified phase) |
0.7267 |
Intermediate Similarity |
NPD1019 |
Discontinued |
0.7261 |
Intermediate Similarity |
NPD2344 |
Approved |
0.7257 |
Intermediate Similarity |
NPD4419 |
Clinical (unspecified phase) |
0.7244 |
Intermediate Similarity |
NPD3748 |
Approved |
0.7244 |
Intermediate Similarity |
NPD2799 |
Discontinued |
0.7241 |
Intermediate Similarity |
NPD1548 |
Phase 1 |
0.7235 |
Intermediate Similarity |
NPD5710 |
Approved |
0.7235 |
Intermediate Similarity |
NPD5711 |
Approved |
0.7234 |
Intermediate Similarity |
NPD7585 |
Approved |
0.7233 |
Intermediate Similarity |
NPD6398 |
Clinical (unspecified phase) |
0.7222 |
Intermediate Similarity |
NPD9493 |
Approved |
0.7219 |
Intermediate Similarity |
NPD1530 |
Clinical (unspecified phase) |
0.7215 |
Intermediate Similarity |
NPD2424 |
Discontinued |
0.7211 |
Intermediate Similarity |
NPD7783 |
Phase 2 |
0.7211 |
Intermediate Similarity |
NPD7782 |
Clinical (unspecified phase) |
0.7205 |
Intermediate Similarity |
NPD6143 |
Clinical (unspecified phase) |
0.7204 |
Intermediate Similarity |
NPD7697 |
Approved |
0.7204 |
Intermediate Similarity |
NPD7698 |
Approved |
0.7204 |
Intermediate Similarity |
NPD7696 |
Phase 3 |
0.7195 |
Intermediate Similarity |
NPD7458 |
Discontinued |
0.7193 |
Intermediate Similarity |
NPD3926 |
Phase 2 |
0.719 |
Intermediate Similarity |
NPD6798 |
Discontinued |
0.7181 |
Intermediate Similarity |
NPD7583 |
Approved |
0.7171 |
Intermediate Similarity |
NPD4908 |
Phase 1 |
0.7171 |
Intermediate Similarity |
NPD1529 |
Clinical (unspecified phase) |
0.7166 |
Intermediate Similarity |
NPD7871 |
Phase 2 |
0.7166 |
Intermediate Similarity |
NPD7870 |
Phase 2 |
0.7162 |
Intermediate Similarity |
NPD1610 |
Phase 2 |
0.7152 |
Intermediate Similarity |
NPD7266 |
Discontinued |
0.7152 |
Intermediate Similarity |
NPD2798 |
Approved |
0.7151 |
Intermediate Similarity |
NPD6823 |
Phase 2 |
0.7143 |
Intermediate Similarity |
NPD6233 |
Phase 2 |
0.7143 |
Intermediate Similarity |
NPD4360 |
Phase 2 |
0.7143 |
Intermediate Similarity |
NPD4363 |
Phase 3 |
0.7143 |
Intermediate Similarity |
NPD6534 |
Approved |
0.7143 |
Intermediate Similarity |
NPD7701 |
Phase 2 |
0.7143 |
Intermediate Similarity |
NPD6535 |
Approved |
0.7134 |
Intermediate Similarity |
NPD651 |
Clinical (unspecified phase) |
0.7133 |
Intermediate Similarity |
NPD1241 |
Discontinued |
0.7124 |
Intermediate Similarity |
NPD3027 |
Phase 3 |
0.7111 |
Intermediate Similarity |
NPD8397 |
Clinical (unspecified phase) |
0.7108 |
Intermediate Similarity |
NPD7615 |
Clinical (unspecified phase) |
0.7091 |
Intermediate Similarity |
NPD3226 |
Approved |
0.7081 |
Intermediate Similarity |
NPD2309 |
Approved |
0.7078 |
Intermediate Similarity |
NPD2313 |
Discontinued |
0.7078 |
Intermediate Similarity |
NPD411 |
Approved |
0.7078 |
Intermediate Similarity |
NPD3268 |
Approved |
0.7078 |
Intermediate Similarity |
NPD1296 |
Phase 2 |
0.7078 |
Intermediate Similarity |
NPD4907 |
Clinical (unspecified phase) |
0.7068 |
Intermediate Similarity |
NPD7874 |
Approved |
0.7068 |
Intermediate Similarity |
NPD7875 |
Clinical (unspecified phase) |
0.7055 |
Intermediate Similarity |
NPD7004 |
Clinical (unspecified phase) |
0.7055 |
Intermediate Similarity |
NPD4662 |
Approved |
0.7055 |
Intermediate Similarity |
NPD4661 |
Approved |
0.7052 |
Intermediate Similarity |
NPD7784 |
Clinical (unspecified phase) |
0.7052 |
Intermediate Similarity |
NPD2403 |
Approved |
0.7051 |
Intermediate Similarity |
NPD1899 |
Clinical (unspecified phase) |
0.7051 |
Intermediate Similarity |
NPD6355 |
Discontinued |
0.7039 |
Intermediate Similarity |
NPD8055 |
Clinical (unspecified phase) |
0.7039 |
Intermediate Similarity |
NPD5647 |
Approved |
0.7031 |
Intermediate Similarity |
NPD7801 |
Approved |
0.7027 |
Intermediate Similarity |
NPD7699 |
Phase 2 |
0.7027 |
Intermediate Similarity |
NPD7700 |
Phase 2 |
0.7025 |
Intermediate Similarity |
NPD1509 |
Clinical (unspecified phase) |
0.7006 |
Intermediate Similarity |
NPD6104 |
Discontinued |
0.7006 |
Intermediate Similarity |
NPD7240 |
Approved |
0.7 |
Intermediate Similarity |
NPD8434 |
Phase 2 |
0.6994 |
Remote Similarity |
NPD7390 |
Discontinued |
0.6993 |
Remote Similarity |
NPD9494 |
Approved |
0.6989 |
Remote Similarity |
NPD1729 |
Discontinued |
0.6982 |
Remote Similarity |
NPD5353 |
Approved |
0.6975 |
Remote Similarity |
NPD6190 |
Approved |
0.6974 |
Remote Similarity |
NPD2797 |
Approved |
0.6962 |
Remote Similarity |
NPD7097 |
Phase 1 |
0.695 |
Remote Similarity |
NPD290 |
Approved |
0.6937 |
Remote Similarity |
NPD2346 |
Discontinued |
0.6923 |
Remote Similarity |
NPD4062 |
Phase 3 |
0.6908
|
Remote Similarity |
NPD3225 |
Approved |